The letter advises that blinatumomab should be withheld if pancreatitis grade 3 occurs, then restarted at 9mcg/day after improvement to grade 1 and escalated to 28mcg/day after 7 days if pancreatitis does not recur. Patients should be advised to recognize features of pancreatitis such as upper abdominal tenderness and pain (made worse by eating), nausea and vomiting. They should be instructed to get medical advice if symptoms occur.